Navigation Links
Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,,Its New Long Acting Drug For Erectile Dysfunction

All Endpoints Met - Up to 88% Efficacy

SEOUL, Korea, March 28, 2007 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. announced today that it has completed a 340 patient phase 2b "at-home" clinical study for udenafil, its new long acting (12 hour half-life) oral phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction (ED). The multi-center study conducted in the U.S. was a randomized, double-blind, placebo controlled study, designed to investigate the efficacy and safety of udenafil in patients with ED. Following a 4-week non-drug baseline period, 340 men with ED of broad etiology and severity were randomized to one of four treatment groups: Placebo, udenafil 50mg, udenafil 100mg or udenafil 150mg. The drug treatment period was 12 weeks with evaluations every 4 weeks. The primary efficacy endpoints were the change in the International Index of Erectile Function (IIEF) Erectile Function Domain (EF) score from baseline to final visit; mean vaginal penetration success rates and mean intercourse completion rates calculated from the Sexual Encounter Profile (SEP) questions 2 and 3, respectively. The study had several secondary efficacy measurements including changes in scores from the other IIEF domains, scores from the remaining SEP questions, changes from baseline in the Patient Self-Assessment Questionnaire (PSAE) and the mean Global Assessment Score (GAQ).

All primary efficacy endpoints were statistically significant compared to placebo. The mean vaginal penetration success rates were 72% (50mg), 88% (100mg) and 82% (150mg) and significantly (p<0.001) higher compared to the 60% observed in the placebo group. The mean intercourse completion rates were 53% (50mg), 66% (100mg) and 69% (150mg) and significantly (p<0.001) higher compared to the 38% observed in the placebo group. Patients reporting improved erections after the 12-week course of therapy were 58% (50mg), 80% (100mg) and 73% (150mg) and signif
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/1/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), an ... markets products that assist healthcare providers in monitoring patients ... the first quarter ended March 31, 2015. ... continued progress with year over year growth of 44% ... said Doug Murphy-Chutorian , M.D., chief executive officer ...
(Date:5/1/2015)... May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... E. Morris , chief financial officer  will be participating ... are as follows: Mizuho Third Annual Healthcare ... Omni Berkshire Place, New York ...
(Date:5/1/2015)... YORK , May 1, 2015  Shares of ... 70% of their value yesterday following the results of ... glaucoma therapy, Rhopressa.  Despite the trial failing to meet ... that positive results may come from future studies. ... brief company overview, current pipeline, financial review, analyst summary, ...
Breaking Medicine Technology:Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... DIEGO, Oct. 20 Aethlon Medical, Inc. (OTC Bulletin ... the Aethlon Hemopurifier® is effective in capturing the current ... Hemopurifier® is the first-in-class medical device able to selectively ... During invitro studies, the Hemopurifier® removed ...
... , WALTHAM, Mass., Oct. 20 Logical Therapeutics, Inc. ... treat medical conditions associated with inflammation, has been selected ... the gastrointestinal (GI) safety of its lead product LT-NS001, ... Annual Scientific Meeting on October 27, 2009. , ...
Cached Medicine Technology:Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus 2Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus 3Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting 2
(Date:5/3/2015)... Francisco, CA (PRWEB) May 03, 2015 ... (CFHI), announced it will be awarding the 2015 ... Jennifer Knight and Selemawit Ghebrendrias, are the deserving recipients ... champion for global service, Harris Llewellyn Wofford. The two ... service and passion for global health. , CFHI ...
(Date:5/3/2015)... Missouri (PRWEB) May 03, 2015 ... business that will directly impact your career? The ... designed for dynamic leaders in multinational companies and ... company. In a changing global landscape, differences in ... and relationships. The EMIB program develops the global ...
(Date:5/3/2015)... HealthPostures, a pioneering ergonomics company ... appearance at the , May 5 - 7, 2015 ... exhibit at the conference include its bestselling TaskMate sit ... is the 6100 TaskMate Executive. Features of the 6100 ... keyboard tray, extended platform work surface and supply holders. ...
(Date:5/2/2015)... 2015 “ ActOn ” was featured on ... look at the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... with organizations to make a difference. , In this material ... things that aren’t about money, which is why those things ...
(Date:5/2/2015)... “ Peachtree Audio ” was featured ... which features the latest and coolest technology products available ... reporter for NewsWatch, conducted the review and shared with ... , Music is an important part of people’s lives ... given the royal treatment. Peachtree Audio does just that ...
Breaking Medicine News(10 mins):Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2
... nations on Friday plans to sign an agreement to ... including HIV/AIDS, TB //and malaria - that largely affect ... ,Under the program, donor countries will ... a preferential price when they are available. This would ...
... reported in the latest Nature Nanotechnology, aims to make ... system has an extremely tiny sieve structure built into ... fluids and separate proteins accurately by size. Conventional separation ... to process. The new microchip system could sort proteins ...
... rare genetic disease, genetics researchers have identified a novel ... human development, potentially in cases of mental retardation and ... identified two genes that contribute to Cornelia deLange syndrome ... one in 10,000 children. The disease varies from milder ...
... published in the latest Lancet raises hopes of prenatal ... //The technology involves separating fetal DNA and mother's DNA ... copies of chromosome 21. ,Currently, available tests ... causes Down's syndrome--are limited by several factors. Screening tests, ...
... Lilly is set on releasing a new line of digital ... Huma-Pen Memoir is thought //to help patients manage their insulin ... hides a hypodermic needle, was unveiled today at Battelle. It ... Eli Lilly, the Indianapolis-based pharmaceutical company. ,The ...
... from Wake Forest University School of Medicine and colleagues, today's ... body fat. // ,Up until age 80, older adults ... of the obesity epidemic - they actually begin their older ... of diabetes, heart disease, high blood pressure, arthritis and disability, ...
Cached Medicine News:Health News:New Microchip for Protein Sorting 2Health News:New Microchip for Protein Sorting 3Health News:Gene Found for Rare Disorder May Reveal New Pathway in Mental Retardation 2Health News:Obesity and Older Adults 2
Liquichek™ Homocysteine Control is a liquid control for monitoring homocysteine test procedures. This product can be used or methods such as HPLC and automated immunoassay procedures....
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
Medicine Products: